By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Ventrus Biosciences, Inc.  

787 7th Avenue
48th Floor
New York  New York  19924  U.S.A.
Phone: 212-554-4267 Fax: 212-554-4314


SEARCH JOBS


Industry
Biotechnology






Company News
Ventrus Biosciences, Inc.  (VTUS) Becomes Assembly Biosciences As Stockholders Approve Merger With Assembly Pharmaceuticals 7/14/2014 6:03:24 AM
Ventrus Biosciences, Inc.  (VTUS) Files And Commences Mailing Of Definitive Proxy Materials For July 10th Annual Meeting 6/10/2014 8:51:46 AM
Ventrus Biosciences, Inc.  (VTUS) To Merge With Assembly Pharmaceuticals 5/19/2014 9:38:24 AM
Ventrus Biosciences, Inc.  (VTUS) Receives Date For Type B Pre-NDA Meeting With FDA For DOLIZEM (Diltiazem Hydrochloride Cream) In Anal Fissures 4/4/2014 7:42:43 AM
Ventrus Biosciences, Inc.  (VTUS) Tanks As Anal Fissure Drug Fails In Trial; Stock Down -63.01% At Market Close (February 12, 2014) 2/12/2014 8:16:22 AM
Ventrus Biosciences, Inc.  (VTUS) Completes Enrollment Of Second Pivotal Phase 3 Trial Of Diltiazem Cream (VEN 307) In Patients With Anal Fissure 11/25/2013 9:23:41 AM
Ventrus Biosciences, Inc.  (VTUS) Shows Off Positive Phase 3 Anal Fissures Data; Stock Soars +15.12% at Market Close (September 11, 2013) 9/11/2013 7:25:57 AM
Ventrus Biosciences, Inc.  (VTUS) Announces Proposed Public Offerings of Common Stock and Series A Convertible Preferred Stock 1/30/2013 9:35:44 AM
Ventrus Biosciences, Inc.  (VTUS) Announces $20 Million Financing 1/30/2013 9:27:38 AM
Ventrus Biosciences, Inc.  (VTUS) Reports Third Quarter 2012 Financial Results 11/14/2012 7:39:35 AM
12345
//-->